An online pharmacy is providing breast cancer patients with a substantially more affordable option for a critical medication, offering potential relief from astronomical drug pricing. SaveRxCanada.to is now distributing a generic version of Palbociclib, a targeted therapy used to treat hormone receptor-positive, HER2-negative advanced breast cancer, at a fraction of the typical U.S. market price.
The medication, marketed under the generic name Palnat and manufactured by licensed pharmaceutical companies in India, costs approximately $4.38 per capsule. A standard monthly treatment at 75 mg per day amounts to $131.40, representing savings of over $10,000 compared to brand-name Ibrance prices in the United States.
Palbociclib works by inhibiting cyclin-dependent kinases, proteins that play a role in cancer cell growth. The drug is typically used in combination with hormone therapies like letrozole or fulvestrant for patients with metastatic breast cancer or advanced stages of the disease.
While the medication offers significant cost benefits, patients should be aware of potential side effects, which include low white blood cell counts, fatigue, nausea, hair thinning, diarrhea, and increased infection risk. More serious but less frequent complications can include blood clots and lung inflammation.
The availability of a more affordable generic version could potentially improve treatment accessibility for patients facing financial barriers to critical cancer medications. Patients interested in this option must obtain a valid prescription from a licensed healthcare provider and work with verified international medication suppliers.
